52
Participants
Start Date
December 31, 2012
Primary Completion Date
September 30, 2015
Study Completion Date
September 30, 2015
SGI-110
SGI-110 will be administered by subcutaneously (SC) on Days 1 - 5 every 28 days until disease progression or unacceptable toxicity
Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center, New York
Fox Chase Cancer Center, Philadelphia
Medical University of South Carolina, Hollings Cancer Center, Charleston
H. Lee Moffitt Cancer Center and Research Institute, Tampa
The Jones Clinic, PC, Germantown
University of Louisville James Graham Brown Cancer Center, Louisville
The Ohio State University Comprehensive Cancer Center, Columbus
UW Carbone Cancer Center, Madison
Northwestern University: Robert H. Lurie Comprehensive Cancer Center, Chicago
Mary Crowley Medical Research Center, Dallas
University of Texas Southwestern Medical Center, Dallas
USC Norris Comprehensive Cancer Center, Los Angeles
City of Hope National Medical Center, Duarte
UC Davis Comprehensive Cancer Center, Sacramento
Swedish Cancer Institute, Seattle
University of British Columbia and Vancouver General Hospital, Vancouver
The Ottawa Hospital Cancer Center, Ottawa
Sunnybrook HealthScience Centre, Toronto
CHUM Hopital St-Luc, Montreal
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke
University of Liverpool Clatterbridge Cancer Center, Liverpool
Cambridge University Hospitals NHS Foundation Trust, London
Imperial College Healthcare NHS Foundation Trust, London
University College London, London
Lead Sponsor
Astex Pharmaceuticals, Inc.
INDUSTRY